Congratulations to ArsenalBio! This Westlake-backed company will receive $70 million for a multi-year collaboration with @Genentech to advance next-generation cell therapies for cancer. Read the press release: bit.ly/3ru4d2l

Congratulations to Mira Chaurushiya, PhD, Senior Partner at Westlake Village BioPartners, for making Business Insider's list of the top 16 pioneers in biotech venture capital. Read the full article here: bit.ly/3s3lijS

Join Westlake’s Mira Chaurushiya, Ph.D. and other biotech leaders on Tuesday, November 1 as they discuss this year’s turbulent market and what the future ahead might look like. Learn more about the topics and speakers here: bit.ly/3DCoPfq

Join Westlake’s Mira Chaurushiya, Ph.D. and other biotech leaders on Tuesday, November 1 as they discuss this year’s turbulent market and what the future ahead might look like. Learn more about the topics and speakers here: bit.ly/3DCoPfq

Today, Weslake-backed ACELYRIN, INC. announced the addition of two veteran C-suite leaders to its team. Read the full press release here: bit.ly/3tiodFQ

We’re thrilled to announce the launch of Westlake-backed Dantari Inc., with $47 million Series A. Proceeds from the financing will support advancement of Dantari’s best-in-class next-gen targeted therapeutics for cancers and other diseases. Learn more: bit.ly/3UAWTOo

Westlake-backed ArsenalBio announced its first patient has been dosed in a Phase 1 clinical trial of AB-1015, in development as a treatment for ovarian cancer. ArsenalBio will provide more details January 10 at the J.P. Morgan 41st Annual Healthcare Conference.

Congratulations to Westlake-backed Neuron23 on initiating dosing in a Phase 1 clinical trial of NEU-723.

Don’t miss Sean Harper’s panel at the Greater Conejo Valley Chamber Regional Economic Forecast on March 10, and keynote by Matthew Fienup, Executive Director of CERF, California Lutheran University. For more information and to register, visit bit.ly/3SOZ8hL.

Congratulations to Westlake-backed ArsenalBio on their collaboration with Thermo Fisher Scientific to support clinical manufacturing of autologous T-cell therapies. Read the press release: bwnews.pr/3nxAWoo bit.ly/3Zkrja0

Congratulations to Westlake-backed ACELYRIN, INC. for appointing Henry Gosebruch to the Company's board of directors. You can read the news release here: prn.to/3M1lVFz

We're thrilled to share that Mira Chaurushiya, Managing Director at Westlake Village BioPartners, has been named one of Endpoints News' LGBTQ+ biopharma leaders for 2023. Congratulations, Mira! Read the article: bit.ly/3ClDhqB #pridemonth #biopharma

Westlake-backed Kate Therapeutics debuts with $51 million Series A to develop next-generation genetic medicines to treat muscle and heart diseases. #genetherapy Read the press release: bit.ly/42wDOkv

Congratulations to our next generation of leaders: Mira Chaurushiya, Ph.D., and David Allison, Ph.D., joining Beth Seidenberg, M.D. as managing directors. These leaders will work together to build great companies from the ground up. Read more: lnkd.in/gRY4YYJW

Beth Seidenberg on the launch of our third fund of $450 million to incubate and grow early stage next-generation #biotechnology companies in the #LosAngeles region and beyond. Read more: bit.ly/3XVyd6s #venturecapital #biotechinvesting

Congratulations to Mira Chaurushiya, Ph.D., and David Allison, Ph.D. These leaders, alongside Beth Seidenberg, M.D., will manage our third fund of $450 million to incubate and grow early stage next-generation #biotechnology companies. Read more: bit.ly/3XVyd6s

Congratulations Westlake-backed Capsida Biotherapeutics and KateTx on their strategic partnership to leverage Capsida's expertise and #AAV manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs. Read more: tinyurl.com/5n83xz23

Welcome to Patricia Turney, who has joined Westlake-backed ACELYRIN as Chief Technical Operations Officer. Patricia is an accomplished supply chain, manufacturing, and QC leader who will support the advancement of ACELYRIN’s programs through late-stage clinical trials.